SPRO Insider Trading Activity and SEC Form 4 Filings
SPRO insider trading summary
Over the past 12 months, insiders at Spero Therapeutics, Inc. (SPRO) reported 9 sales worth $552K by 2 insiders and no open-market purchases on SEC Form 4. Net insider selling was $552K.
Latest SPRO insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| May 4, 2026 | Esther Rajavelu | See Remarks | Sell | $63K (25,240 @ $2.51) |
| Feb 6, 2026 | Timothy Keutzer | Chief Operating Officer | Sell | $44K (18,652 @ $2.36) |
| Feb 6, 2026 | Esther Rajavelu | See Remarks | Sell | $120K (50,816 @ $2.36) |
| Feb 6, 2026 | Esther Rajavelu | See Remarks | Sell | $88K (37,101 @ $2.36) |
| Feb 4, 2026 | Timothy Keutzer | Chief Operating Officer | Sell | $8K (3,471 @ $2.24) |
| Feb 3, 2026 | Timothy Keutzer | Chief Operating Officer | Sell | $52K (24,224 @ $2.14) |
| Feb 2, 2026 | Timothy Keutzer | Chief Operating Officer | Sell | $42K (18,891 @ $2.20) |
| Feb 2, 2026 | Esther Rajavelu | See Remarks | Sell | $41K (18,442 @ $2.20) |
| Nov 7, 2025 | Esther Rajavelu | See Remarks | Sell | $95K (40,270 @ $2.37) |
| Aug 28, 2025 | Ankit Mahadevia | Insider | Sell | $13K (6,572 @ $1.97) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.